Comparative analysis of IL-1β blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of PD-L1 expression in malignant tissues of the patients with various solid tumors

The action of checkpoint inhibitors is based on activation of T cell antitumor immunity, and, therefore, the search for markers of lymphocyte functional activity before starting the therapy is highly relevant. Determination of the PD-L1 expression in tumor tissues reflects immunosuppressive activity...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	R. V. Orlova, N. V. Zhukova, A. M. Malkova, E. A. Kaledina, A. R. Gubal, V. V. Sharoiko
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2021
Materias:	il-1β neutrophil-to-lymphocyte ratio pd-l1 correlation solid tumors immune therapy Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/89e5e681f839483e8ece0ac509e6432f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:89e5e681f839483e8ece0ac509e6432f
record_format	dspace
spelling	oai:doaj.org-article:89e5e681f839483e8ece0ac509e6432f2021-11-18T08:03:51ZComparative analysis of IL-1β blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of PD-L1 expression in malignant tissues of the patients with various solid tumors1563-06252313-741X10.15789/1563-0625-CAO-2197https://doaj.org/article/89e5e681f839483e8ece0ac509e6432f2021-11-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/2197https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XThe action of checkpoint inhibitors is based on activation of T cell antitumor immunity, and, therefore, the search for markers of lymphocyte functional activity before starting the therapy is highly relevant. Determination of the PD-L1 expression in tumor tissues reflects immunosuppressive activity of malignant cells, and it is used as a predictive marker in clinical practice. The ratio of neutrophils to lymphocytes in tumor tissue and in peripheral blood can also indicate the activity of adaptive immunity and correlates with the efficacy of therapy. It has been shown that a high level of interleukin 1 beta in the tumor microenvironment is associated with immunosuppression of lymphocytes and, possibly, reflects the activity of the tumor microenvironment. The aim of this work is to study the relationship between tumor expression of PD-L1, the concentration of serum interleukin-1 beta and the ratio of neutrophils and lymphocytes in peripheral blood.Before starting therapy with checkpoint inhibitors in patients with various solid tumors (n = 50), the serum level of interleukin-1 beta was determined by ELISA (ELISA-Best, Novosibirsk, Russia), expression of PD-L1 in the tumor by immunohistochemical method, complete blood count was performed using cytometry. Statistical analysis was performed in GraphPad Prism 6 (Graph Pad Software, USA) using the statistical methods of Fisher, Mann-Whitney, and Spearman.The average value of the index of the ratio of neutrophils and lymphocytes (NLR) in peripheral blood was 2.65± 0.21 (95% CI 2.22-3.07). The index value of more than 3.5 was found in 18% (9/50) of patients. The mean value of the PD-L1 expression level was 23.02±4.52% (95% CI 13.86-32.18). Expression of PD-L1 in tumor tissue was detected in 60.1% (25/40) of patients, among whom an increased expression of more than 50% was detected in 20.0% (5/25) of cases. A positive weak correlation was found between the concentration of interleukin 1 beta and the number of leukocytes (r = 0.34; p = 0.019) and index (r = 0.32; p = 0.029). The level of PD-L1 expression in tumor tissue also had a weak positive correlation with the serum interleukin 1 beta concentration (r = 0.33; p = 0.037) and the neutrophil-lymphocyte ratio (r = 0.33; p = 0.034). In the group of patients with PD-L1 expression > 5%, the mean value of the concentration of interleukin 1 beta was 1.65±0.62 pg/ml, and the mean value of the index was 4.26±0.94 х 10 9/l, which exceeds the values groups with undetectable PD-L1, but the differences were not statistically significant.The obtained result may indicate the influence of the immunosuppressive properties of the tumor on the state of the patient's immunity. Comprehensive determination of tumor PD-L1 expression, serum interleukin 1 beta concentration and the ratio of neutrophils and lymphocytes in peripheral blood can be used as an assessment of the patient's immune status before starting treatment with checkpoint inhibitors.R. V. OrlovaN. V. ZhukovaA. M. MalkovaE. A. KaledinaA. R. GubalV. V. SharoikoSPb RAACIarticleil-1βneutrophil-to-lymphocyte ratiopd-l1correlationsolid tumorsimmune therapyImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 23, Iss 5, Pp 1105-1114 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	il-1β neutrophil-to-lymphocyte ratio pd-l1 correlation solid tumors immune therapy Immunologic diseases. Allergy RC581-607
spellingShingle	il-1β neutrophil-to-lymphocyte ratio pd-l1 correlation solid tumors immune therapy Immunologic diseases. Allergy RC581-607 R. V. Orlova N. V. Zhukova A. M. Malkova E. A. Kaledina A. R. Gubal V. V. Sharoiko Comparative analysis of IL-1β blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of PD-L1 expression in malignant tissues of the patients with various solid tumors
description	The action of checkpoint inhibitors is based on activation of T cell antitumor immunity, and, therefore, the search for markers of lymphocyte functional activity before starting the therapy is highly relevant. Determination of the PD-L1 expression in tumor tissues reflects immunosuppressive activity of malignant cells, and it is used as a predictive marker in clinical practice. The ratio of neutrophils to lymphocytes in tumor tissue and in peripheral blood can also indicate the activity of adaptive immunity and correlates with the efficacy of therapy. It has been shown that a high level of interleukin 1 beta in the tumor microenvironment is associated with immunosuppression of lymphocytes and, possibly, reflects the activity of the tumor microenvironment. The aim of this work is to study the relationship between tumor expression of PD-L1, the concentration of serum interleukin-1 beta and the ratio of neutrophils and lymphocytes in peripheral blood.Before starting therapy with checkpoint inhibitors in patients with various solid tumors (n = 50), the serum level of interleukin-1 beta was determined by ELISA (ELISA-Best, Novosibirsk, Russia), expression of PD-L1 in the tumor by immunohistochemical method, complete blood count was performed using cytometry. Statistical analysis was performed in GraphPad Prism 6 (Graph Pad Software, USA) using the statistical methods of Fisher, Mann-Whitney, and Spearman.The average value of the index of the ratio of neutrophils and lymphocytes (NLR) in peripheral blood was 2.65± 0.21 (95% CI 2.22-3.07). The index value of more than 3.5 was found in 18% (9/50) of patients. The mean value of the PD-L1 expression level was 23.02±4.52% (95% CI 13.86-32.18). Expression of PD-L1 in tumor tissue was detected in 60.1% (25/40) of patients, among whom an increased expression of more than 50% was detected in 20.0% (5/25) of cases. A positive weak correlation was found between the concentration of interleukin 1 beta and the number of leukocytes (r = 0.34; p = 0.019) and index (r = 0.32; p = 0.029). The level of PD-L1 expression in tumor tissue also had a weak positive correlation with the serum interleukin 1 beta concentration (r = 0.33; p = 0.037) and the neutrophil-lymphocyte ratio (r = 0.33; p = 0.034). In the group of patients with PD-L1 expression > 5%, the mean value of the concentration of interleukin 1 beta was 1.65±0.62 pg/ml, and the mean value of the index was 4.26±0.94 х 10 9/l, which exceeds the values groups with undetectable PD-L1, but the differences were not statistically significant.The obtained result may indicate the influence of the immunosuppressive properties of the tumor on the state of the patient's immunity. Comprehensive determination of tumor PD-L1 expression, serum interleukin 1 beta concentration and the ratio of neutrophils and lymphocytes in peripheral blood can be used as an assessment of the patient's immune status before starting treatment with checkpoint inhibitors.
format	article
author	R. V. Orlova N. V. Zhukova A. M. Malkova E. A. Kaledina A. R. Gubal V. V. Sharoiko
author_facet	R. V. Orlova N. V. Zhukova A. M. Malkova E. A. Kaledina A. R. Gubal V. V. Sharoiko
author_sort	R. V. Orlova
title	Comparative analysis of IL-1β blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of PD-L1 expression in malignant tissues of the patients with various solid tumors
title_short	Comparative analysis of IL-1β blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of PD-L1 expression in malignant tissues of the patients with various solid tumors
title_full	Comparative analysis of IL-1β blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of PD-L1 expression in malignant tissues of the patients with various solid tumors
title_fullStr	Comparative analysis of IL-1β blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of PD-L1 expression in malignant tissues of the patients with various solid tumors
title_full_unstemmed	Comparative analysis of IL-1β blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of PD-L1 expression in malignant tissues of the patients with various solid tumors
title_sort	comparative analysis of il-1β blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of pd-l1 expression in malignant tissues of the patients with various solid tumors
publisher	SPb RAACI
publishDate	2021
url	https://doaj.org/article/89e5e681f839483e8ece0ac509e6432f
work_keys_str_mv	AT rvorlova comparativeanalysisofil1bbloodserumconcentrationneutrophiltolymphocytesratioinperipheralbloodandthelevelsofpdl1expressioninmalignanttissuesofthepatientswithvarioussolidtumors AT nvzhukova comparativeanalysisofil1bbloodserumconcentrationneutrophiltolymphocytesratioinperipheralbloodandthelevelsofpdl1expressioninmalignanttissuesofthepatientswithvarioussolidtumors AT ammalkova comparativeanalysisofil1bbloodserumconcentrationneutrophiltolymphocytesratioinperipheralbloodandthelevelsofpdl1expressioninmalignanttissuesofthepatientswithvarioussolidtumors AT eakaledina comparativeanalysisofil1bbloodserumconcentrationneutrophiltolymphocytesratioinperipheralbloodandthelevelsofpdl1expressioninmalignanttissuesofthepatientswithvarioussolidtumors AT argubal comparativeanalysisofil1bbloodserumconcentrationneutrophiltolymphocytesratioinperipheralbloodandthelevelsofpdl1expressioninmalignanttissuesofthepatientswithvarioussolidtumors AT vvsharoiko comparativeanalysisofil1bbloodserumconcentrationneutrophiltolymphocytesratioinperipheralbloodandthelevelsofpdl1expressioninmalignanttissuesofthepatientswithvarioussolidtumors
_version_	1718422297723797504

Comparative analysis of IL-1β blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of PD-L1 expression in malignant tissues of the patients with various solid tumors

Ejemplares similares